anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the KNTC2 gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The inventive peptides encompass both KNTC2-derived peptides and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding such peptides as well as pharmaceutical compositions that include any such peptides or polynucleotides as active agents. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of a metastatic- or post-operative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from KNTC2, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
Advanced life support (ALS) is an important training course for junior physicians to learn how to manage critical patients. Ultrasound is an indispensable and easily accessible tool in emergency departments and critical care settings. Current guidelines suggested that ultrasound could be an integral part of resuscitative medicine. However, structured training is needed for better efficacy of ultrasound use during clinical use. The aim of this project is to incorporate ultrasound into the ALS course, including common critical diseases, such as dyspnea, shock, major trauma and cardiac arrests. Junior physicians at the National Taiwan University Hospital will be enrolled in this study as participants. Through lectures and hand-on practice, the junior physicians could be familiar with managing critical patients with ultrasound assistance. This study will be lasted for two years. In the 1st year, the investigators will establish the echo-assisted ALS (eALS) training course, set up assessment modules and simulation scenarios. In the 2nd year, the investigators will provide the formal eALS training course for 4 to 6 times, analyze the data and establish on-line learning modules. In addition, the investigators will promote the eALS course to other hospitals and other countries.

This pioneer study can provide experience of eALS training course and contribute to current medical education. Moreover, it can improve decision-making process and quality of care of the participants. Furthermore, the integrated on-line learning programs can be used to lessen the maturation time of the participants and would provide them to other departments and hospitals to improve patients' care.
Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
CYSTADANE (betaine anhydrous for oral solution) is an agent for the treatment of homocystinuria. It contains no ingredients other than anhydrous betaine. CYSTADANE is a white, granular, hygroscopic powder, which is diluted in water and administered orally. The chemical name of betaine anhydrous powder is trimethylglycine. It has a molecular weight of 117.15. The structural formula is:
Patients receive TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) via IV day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
A method of disinfecting  Candida auris  is disclosed including treating a surface with a solution comprising 3,4-Dihydroxybenzoic acid ethyl ester. The solution may further include protocatechuic acid. The solution may include an alcohol. The alcohol may include methanol, ethanol, or isopropyl alcohol. The surface may include a solid surface, a porous or semi-porous surface, or a cloth-like surface. The surface may include a surface on skin, clothes, masks, a medical device, food processing equipment, hearing aid or a surgical implant. The surface may include a surface in a healthcare facility.
OBJECTIVE: Operative interposition of material between the trigeminal nerve and offending artery for surgical treatment of drug-resistant trigeminal neuralgia (TGN), following the Jannetta method, has been proven to be the most successful invasive treatment. Reexplorations of patients with recurrence of TGN have revealed nerve root irritations and scarring due to interposed material. To prevent these complications, modifications of microvascular decompression (MVD) aim at transposing the vessel away from the trigeminal nerve, without attachment of additional material to the nerve root. Given that both techniques (interposition and transposition) have been performed in the authors' institution, they decided to analyze them for the short- and midterm outcomes.
METHODS: All patients who had undergone MVD for drug-resistant TGN in the authors' institution between 2008 and 2022 were analyzed retrospectively. Outcome at discharge and follow-up was evaluated using the Barrow Neurological Institute pain intensity score. Additionally, complications and pain recurrence were assessed.
RESULTS: A total of 114 patients were operated on using transposition and 110 patients were treated using interposition. For transposition 102 patients were followed up for a median of 31.5 months, and for interposition 100 patients were followed up for a median of 95 months. At discharge 92.1% versus 94.5% of patients in the transposition and interposition groups, respectively, experienced a good outcome (Barrow Neurological Institute pain intensity scores I-III). At follow-up, 83.3% versus 85% of patients in the transposition and interposition groups, respectively, continued to demonstrate a good outcome. In 4.9% of patients in the transposition group and in 6% of patients in the interposition group, recurrence of pain occurred. Complications occurred in 24.6% of patients in the transposition and in 27.3% of those in the interposition group. The most frequent complications were facial hypesthesia (10.5% vs 11.8%, transposition vs interposition), followed by CSF leaks (2.6% vs 8.2%).
CONCLUSIONS: Transposition for MVD is an elegant way of solving vessel-nerve conflicts at the cerebellopontine angle. Similar to interposition, transposition shows positive short- and midterm outcomes for patients experiencing drug-resistant TGN. However, the main objective of transposition, which is improved prevention of recurrence and reduction of complications at the trigeminal nerve, could not be confirmed in this study.
The invention discloses a polypeptide substance, preparation method and application thereof. The invention also discloses extraction process of two polypeptides, and determines molecular weight and amino acid sequence of the polypeptides. The polypeptides are synthesized by the chemical method, and purity analysis and molecular weight measurement results of the polypeptides indicate that molecular ion peak (m/z) completely satisfies theoretical molecular weight. Amino acid analysis result of the polypeptides indicates that amino acid content and the composition of the peptides are in accordance with theoretical values. Amino acid sequence measurement result of the polypeptides indicates primary structure thereof is in accordance with the designed sequence. At the same time, activity measurement result of the polypeptides indicates that the two peptides have activity, and remarkable effect on the treatment of myocardial ischemia, cerebral ischemia, and hepatic ischemia.
The rotator cuff was divided into three parts according to the arthroscopic discovery: (1) the anterior part which contained the subsacpularis and one third of the suprascapularis forward; (2) the middle part which contained the two thirds of the suprascapularis backward and one third of the subscapularis forward; (3) the posterior part which contained two thirds of subscapularis backward and teres minor. The patients with rotator cuff tear at the anterior part were categorized in the anterior tear group.
Clinical dose escalation drug trial to evaluate the effect of 3 different doses of dexmedetomidine on the pulmonary vascular bed in pediatric subjects with elevated pulmonary vascular resistance. The study will be conducted in 2 parts, with a pilot phase incorporating stopping rules to optimize safety of the drug in this population. Study subjects will include pediatric subjects with Pulmonary Hypertension (PHTN).

Part 1: This will be the dose escalation phase of the study. Twenty four evaluable subjects will be enrolled. Subjects will include pediatric subjects with pulmonary hypertension (PVR\>4WU) undergoing hemodynamic cardiac catheterization and vasoreactivity drug testing. Cohorts of 8 evaluable subjects will receive dose level 1, dose level 2, or dose level 3 of Dexmedetomidine (DEX). The dose will be escalated to the next dose of DEX once all subjects have been enrolled in the preceding DEX dose cohort, and safety has been established at that level. Inadequate sedation despite the highest dose of DEX at each level will be considered a treatment failure on an intention to treat basis. Part 2: This part of the study will be conducted after the pilot phase is safely completed, and the full complement of subjects will be recruited.
Regional citrate anticoagulation is the gold standard of anticoagulation in patient receiving CRRT. In RCA circuit, there was a monitoring of pre-filter (systemic) ionized calcium and post-filter (circuit) ionized calcium. Pre-filter ionized calcium was monitored for observe the adverse effect of citrate such as hypocalcemia, citrate intoxication. However, post-filter ionized calcium was monitored for adjustment the citrate dose. We find many problem with frequently monitoring of post-ionized calcium such as confusion from markedly abnormal result, how to adjustment the citrate dose ,and increase workload for nurses. We hypothesis that if we can monitoring of post-filter ionized calcium?
Within the scope of the study, a total of at least 60 athletes, between the ages of 9-18, who have been training archery at least twice a week for at least 2 years, who have not changed their bow category since it started, who do not have a temporomandibular joint problem, and who volunteer to participate in the study, will be recruited in equal numbers from each age category. Within the scope of evaluation; Demographic information and features regarding archery equipment will be recorded. Within the scope of anthropometric measurements; adipose tissue measurements with skinfold; circumference measurements and length measurements with tape measure; diameter measurements with caliper; Facial anthropometric measurements will be measured with a caliper/tape measure. Formulary named "Heath-Carter Anthropometric Somatotype Technique" to determine the body somatotypes of athletes; Lateral photography for biomechanical evaluation of the craniocervical region; Hand Grip Strength Test for performance evaluation; Corbin Postural Assessment Scale will be used for posture evaluation. In order to determine the shooting performance, the athletes' actual competition scores in the last year will be recorded. Medicine ball throwing test, upper extremity y balance test and closed kinetic chain upper extremity stability test will be used to evaluate upper extremity performance. For statistical analysis, normal distribution of parameters will be examined. To determine the relationship between shooting performance and stabilization and related parameters, Pearson test will be used for normally distributed parameters and Spearman correlation test will be used for non-normally distributed parameters.
Complex is described which is insoluble in water and aqs. fluids and which complexes halogen molecules by charge transfer or by van der Waal's forces. The complex is formed by contacting polyvinyl pyrrolidone polyamides, copolymers or polycondensates contg. (active) C with molecular I2. The complex is used to sterilise fluids which contact mucous membranes or other living tissues, render water and gases aseptic, in horticulture as fungicides and in (veterinary) medicine. They are also used in the hygiene/dermatology sectors (e.g. in soaps, pomades, toothpastes, chewing gum), all these uses involving suitable I2 concentrations. The complexes only lose a max. of 1-3% of the I2 introduced and do not alter the taste, smell or quality of any water treated although the I2 is present in the active, molecular, form.
BACKGROUND: Seizures are relatively common among children with HIV in low- and middle-income countries and are associated with significant morbidity and mortality. Early treatment with antiretroviral therapy (ART) may reduce this risk by decreasing rates of central nervous system infections and HIV encephalopathy.
METHODS: We conducted a prospective, unmatched case-control study. We enrolled children with new-onset seizure from University Teaching Hospital in Lusaka, Zambia and 2 regional hospitals in rural Zambia. Controls were children with HIV and no history of seizures. Recruitment took place from 2016 to 2019. Early treatment was defined as initiation of ART before 12 months of age, at a CD4 percentage >15% in children aged 12-60 months or a CD4 count >350 cells/mm 3 for children aged 60 months or older. Logistic regression models were used to evaluate the association between potential risk factors and seizures.
RESULTS: We identified 73 children with new-onset seizure and compared them with 254 control children with HIV but no seizures. Early treatment with ART was associated with a significant reduction in the odds of seizures [odds ratio (OR) 0.04, 95% confidence interval: 0.02 to 0.09; P < 0.001]. Having an undetectable viral load at the time of enrollment was strongly protective against seizures (OR 0.03, P < 0.001), whereas history of World Health Organization Stage 4 disease (OR 2.2, P = 0.05) or CD4 count <200 cells/mm 3 (OR 3.6, P < 0.001) increased risk of seizures.
CONCLUSIONS: Early initiation of ART and successful viral suppression would likely reduce much of the excess seizure burden in children with HIV.
1422745 Inhibiting aggresive behaviour UNIROYAL INC 26 June 1973 [21 Aug 1972] 30219/73 Heading A5B A method of preventing or inhibiting aggresive behaviour in an animal comprises administering to the animal an amount of 4-hydroxy-1, 2,3-benzotriazine effective to prevent or inhibit said behaviour in the animal without simultaneously causing depression in said subject. The compound may be .administered in an orally administerable dosage form, e.g. a pill, tablet, capsule, solution or suspension, or may be parenterally administered e.g. as a solution or suspension or rectally administered e.g. as a suppository. The effective amount is preferably 2-100 mg/kg of body weight of animal per day.
PURPOSE:To obtain a transparent cosmetic having a beautiful appearance, not giving a foreign touch on its usage and having a three-dimensional pattern stable with time, by embedding a shaped product in a transparent gel base material and subsequently returning temperature of the embedded shaped product to room temperature, the shaped product being produced by adding a colorant and an emulsifier to the same kind of a transparent gel base material as the above-mentioned gel base material, molding the mixture and subsequently solidifying the molded product by cooling. CONSTITUTION:A shaped product is embedded in a transparent gel base material obtained from a water-soluble polymer (e.g. methyl cellulose) or an inorganic gelling agent (e.g. sodium magnesium silicate), and subsequently allowed to stand at room temperature to return the temperature of the solidified shaped product to room temperature, thus obtaining a transparent cosmetic in which the three-dimensional pattern of the shaped product is formed. The shaped product is produced by adding a colorant (especially preferably a water-dispersible coloring agent) and/or an emulsifier (preferably an O/W emulsifier) to the same kind of a transparent gel base material as the above-mentioned transparent gel base material, molding the mixture and subsequently solidifying the molded product by cooling preferably at approximately -10 deg.C. Thereby, a transparent cosmetic having a beautiful appearance, not giving a foreign touch on its usage, having good usability and having the three-dimensional pattern stable with time therein.
Participants in this arm will receive norepinephrine as a bolus dose to treat maternal hypotension during cesarean section under spinal anesthesia. The dosage will be determined using the upper and lower sequential distribution method (UDM). The aim is to investigate the effective dose (ED50 and ED95) of norepinephrine in maintaining maternal blood pressure stability and optimizing maternal outcomes during the procedure.
Percutaneous transhepatic biliary drainage (PTBD) is commonly used in the treatment of malign and benign biliary pathologies. Certain complications after PTBD may occur, such as biliary fistula, biliary leakage, bilioma, and hematoma. The purpose of this study was to evaluate the safety and effectiveness of using a sterile gelatin sponge to seal the biliary tract after PTBD in patients with liver transplants to prevent complications. A total of 131 biliary drainages were introduced in 97 patients, and a sterile gelatin sponge was used to seal the biliary tract after removal of the biliary drainage catheter. The patients were immediately examined for complications using ultrasound and then followed up clinically unless imaging was required. Five fluid collections within the liver with a diameter <2 cm, consistent with hematoma or bilioma, were resolved spontaneously. No hematoma or bilioma required treatment, and no biliary leakage or fistula was detected. No compli¬cations related to the use of the sponge were observed. The use of a sterile gelatin sponge is a safe and effec-tive method for sealing the biliary tract to prevent complications after PTBD in patients with liver transplants.
Participants received 0.1 mg/kg BVS857 i.v. weekly for 12 weeks.
Study Design, Patients, and Procedures This was a prospective, single-center, observational study conducted in children with ALL between November 2018 and June 2022. Children with newly diagnosed B-ALL who undergone NGS of B-cell receptors at the Children's Hospital of Zhejiang University School of Medicine were included in this study.

The European Group for the Immunological Characterization of Leukemias (EGIL) criteria were applied to diagnose and classify ALL in this study. All enrolled patients were treated according to the ZJCH-ALL-2019 protocol detailed in the supplementary file. This protocol was implemented in our center in September 2018 and subsequently extended to all of Zhejiang Province in 2019. In this protocol, NGS-MRD was not used for patient risk stratification or treatment allocation. For the detection of MRD, bone marrow (BM) aspiration for Ig NGS was collected at diagnosis, the end of induction (EOI) at the 5th week from the initial prednisone prephase, and the end of consolidation (EOC) at the 13th week which was before the start of early intensification for low and intermediate risk patients, and was before the start of the second course of consolidation for high-risk patients. NGS-MRD was sequentially monitored every 2 to 3 months after consolidation until it was undetectable. In this study, NGS-MRD refers to the quantitative value of MRD detected through NGS testing which was the sum of IGH and light chain (IGK/IGL) levels. NGS detection during other timepoints, such as the interim of induction and timepoints after NGS-MRD was negative, was not mandatory but monitored as per parents' preference. The patients were followed up until August 30, 2022 and the median follow-up time was 20.7 months.

Statistical Analysis The association between categorical variables was tested using χ2 test, the correlation between quantitative variables was measured using Pearson correlation and tested using Student's t distribution, and ANOVA was used to compare quantitative variables. Event-free survival (EFS) and overall survival (OS) curves were estimated using the Kaplan-Meier method and compared according to the log rank test. Death during induction, abandonment before complete remission, death in continuous complete remission, relapse, and secondary malignancies were considered as events in the calculation of EFS probability. The EFS time was calculated from the date of diagnosis to the last date of follow-up or the first event. The OS was calculated from the date of diagnosis to death from any causes with censoring the patients alive at the time of data analysis. The final date for follow-up was August 30, 2022. Data visualization was performed using R package ggplot2 (Version 4.0.3) and GraphPad Prism 9.0.0. Statistical analysis was performed on R (Version 4.0.3). A P value of \<0.05 (2 tailed) was considered to be statistically significant.
Pathological cardiac hypertrophy (CH) may lead to heart failure and sudden death. MicroRNAs (miRNAs) have been documented to play crucial parts in CH. The objective of this research was to discuss the potential along with molecule mechanism of miR-495-3p in CH. In vivo CH model was induced by aortic banding (AB) in rats. Cellular hypertrophy in H9c2 rat cardiomyocytes was stimulated by angiotensin II (Ang II) treatment. Haematoxylin and eosin (HE), echocardiography and immunofluorescence staining were used to examine the alterations in cardiac function. The outcomes showed that miR-495-3p expression was high in rat model as well as in Ang II-stimulated cardiomyocytes. Besides, silenced miR-495-3p attenuated CH both in vitro and in vivo. Mechanically, miR-495-3p bound to pumilio RNA binding family member 2 (Pum2) 3'UTR and silenced its expression. Rescue assays further notarized that Pum2 silence abrogated the inhibitory impacts of miR-495-3p inhibitor on CH. In a word, the present research uncovered that miR-495-3p promoted CH by targeting Pum2. Therefore, miR-495-3p may be a novel therapeutic molecule for this disease.